Moderna, Inc.

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-24 pm EST			5-day change	1st Jan Change
41.41 ^USD	-2.31%		+21.58%	-0.41%

Jan. 24	Health Care Up on Novo Nordisk Optimism -- Health Care Roundup	DJ
Jan. 24	S&P 500 Posts Weekly Gain Amid Earnings Beats, Start of Trump Presidency	MT

MODERNA : Berenberg sticks Neutral

November 19, 2024 at 02:05 am EST

In a research note, Berenberg analyst Harry Gillis has maintained his recommendation on the stock with a Neutral rating. The target price remains unchanged at USD 42.

Latest news about Moderna, Inc.

Health Care Up on Novo Nordisk Optimism -- Health Care Roundup	Jan. 24	DJ
S&P 500 Posts Weekly Gain Amid Earnings Beats, Start of Trump Presidency	Jan. 24	MT
Sector Update: Health Care Stocks Decline Premarket Friday	Jan. 24	MT
Moderna to Supply COVID-19 Vaccines in EU, Norway	Jan. 24	MT
Moderna Wins Tender to Supply its COVID-19 Vaccine in the European Union	Jan. 24	MT
Moderna: Covid vaccine contract with 15 EU countries	Jan. 24	CF
Moderna, Inc. Receives Tender for Supply of its mRNA COVID-19 Vaccine in European Union	Jan. 24	CI
Sector Update: Health Care Stocks Higher Late Afternoon	Jan. 21	MT
Top Midday Gainers	Jan. 21	MT
Sector Update: Health Care Stocks Gain in Afternoon Trading	Jan. 21	MT
US Equity Indexes Rise as Treasury Yields Mixed After Trump Administration Avoids Fanning Inflation Expectations	Jan. 21	MT
Sector Update: Health Care	Jan. 21	MT
US Equity Indexes Rise in Midday Trading	Jan. 21	MT
Top Midday Stories: Charles Schwab's Adjusted Earnings Rise; Apple Q4 China Sales Reportedly Drop	Jan. 21	MT
Global markets live: Chevron, Amazon, GSK, Intel, Zalando...	Jan. 20
Moderna Lands $590 Million for Bird Flu Vaccine Development in US	Jan. 19	MT
Moderna Gets $590 Million of Federal Funding For Bird Flu Vaccine -- Update	Jan. 17	DJ
Moderna Gets $590 Million From US Government for Influenza Vaccine Program; Shares Rise After Hours	Jan. 17	MT
US awards Moderna $590 million for bird flu vaccine development	Jan. 17	RE
S&P 500 Logs 2.9% Weekly Gain on Easing Inflationary Pressures, Strong Bank Earnings	Jan. 17	MT
Moderna Gets $590 Million of Federal Funding For Influenza Vaccines	Jan. 17	DJ
Berenberg Bank Adjusts Moderna Price Target to $33 From $42, Maintains Hold Rating	Jan. 16	MT
Banks, bulls and tame inflation	Jan. 16
Analyst recommendations: Datadog, Estee Lauder, Netflix, Moderna, EasyJet...	Jan. 16
Moderna Struggles with COVID-19 Vaccine Market Share, Pipeline Progress, Morgan Stanley Says	Jan. 15	MT

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (97.4%); - grant revenue (1.4%); - revenue from collaboration agreements (1.2%). At the end of 2023, the group possessed a portfolio of 41 products in clinical development, of which 6 in phase III, 12 in phase II and 18 in phase I, and 5 products in preclinical development. Net sales are distributed geographically as follows: the United States (27.7%), Europe (19.8%) and other (52.5%).

Employees

5,600

Sector

Biotechnology & Medical Research

Calendar

2025-02-13 - Q4 2024 Earnings Call

More about the company